Clinical Trials
Medigene receives approvals for its first clinical trial with TCR therapy MDG1011
Medigene AG announced that the German Senior Federal Authority "Paul-Ehrlich-Institute" (PEI) and the relevant ethics committee have approved the study design of the first planned...
Clinical Trials
Vertex announces positive results of phase 2 study of Nav1.8 inhibitor VX -150 for Acute pain
Vertex Pharmaceuticals Inc announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery. ...
Clinical Trials
OTEZLA® (Apremilast) Phase II Data Showed Clinically significant Improvements in Patients with Active Ulcerative Colitis
Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed...
Clinical Trials
OTEZLA (Apremilast) Phase III Data Showed good results among Patients with Active Behçet’s Disease with Oral Ulcers
Celgene Corporation announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet's Disease with oral ulcers were...
Clinical Trials
Indian Government to come out with a new pharma policy
The government is looking to bring in a new pharma policy for implementing the proposed healthcare plan across the country in the next couple of...
Clinical Trials
Flex Databases is Beginning to Implement Blockchain Technology in Our IT Systems That Manage Clinical Trial Studies
The past few years have created something of a boom in the development of Blockchain technology and its emerging applications within various industries and spheres...
Clinical Trials
ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC
ZZ Biotech announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.